ReP USP - Resultado da busca

Filtros : "Chiu, Derek S." Limpar

Filtros

Collaboration
Normalized affiliation
Non normalized affiliation
- british columbia's gynecological cancer research team (ovcare), university of british columbia, bc cancer, and vancouver general hospital, vancouver, bc (1)
- british columbia's ovarian cancer research (ovcare) program, bc cancer, vancouver general hospital, and university of british columbia, vancouver, bc (1)
- canada's michael smith genome sciences centre, bc cancer, vancouver, bc (1)
- cancer research uk cambridge institute, university of cambridge, cambridge (1)
- centre for cancer genetic epidemiology, department of oncology, university of cambridge, cambridge (1)

Artigo de periodico
Profiling the immune landscape in mucinous ovarian carcinoma (2023)
Meagher, Nicola S.; Hamilton, Phineas; Milne, Katy; Thornton, Shelby; Harris, Bronwyn; Weir, Ashley; Alsop, Jennifer; Bisinoto, Christiani; Brenton, James D.; Brooks-Wilson, Angela; Chiu, Derek S.; Reis, Francisco José Candido dos ; Ramus, Susan J; Cook, Linda S.
Source: Gynecologic Oncology. Unidade: FMRP
Subjects: CARCINOMA, NEOPLASIAS OVARIANAS, FATORES DE TRANSCRIÇÃO, ANTÍGENOS, LINFÓCITOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MEAGHER, Nicola S. et al. Profiling the immune landscape in mucinous ovarian carcinoma. Gynecologic Oncology, v. 168, p. 23-31, 2023Tradução . . Disponível em: https://doi.org/10.1016/j.ygyno.2022.10.022. Acesso em: 07 nov. 2024.
APA
Meagher, N. S., Hamilton, P., Milne, K., Thornton, S., Harris, B., Weir, A., et al. (2023). Profiling the immune landscape in mucinous ovarian carcinoma. Gynecologic Oncology, 168, 23-31. doi:10.1016/j.ygyno.2022.10.022
NLM
Meagher NS, Hamilton P, Milne K, Thornton S, Harris B, Weir A, Alsop J, Bisinoto C, Brenton JD, Brooks-Wilson A, Chiu DS, Reis FJC dos, Ramus SJ, Cook LS. Profiling the immune landscape in mucinous ovarian carcinoma [Internet]. Gynecologic Oncology. 2023 ; 168 23-31.[citado 2024 nov. 07 ] Available from: https://doi.org/10.1016/j.ygyno.2022.10.022
Vancouver
Meagher NS, Hamilton P, Milne K, Thornton S, Harris B, Weir A, Alsop J, Bisinoto C, Brenton JD, Brooks-Wilson A, Chiu DS, Reis FJC dos, Ramus SJ, Cook LS. Profiling the immune landscape in mucinous ovarian carcinoma [Internet]. Gynecologic Oncology. 2023 ; 168 23-31.[citado 2024 nov. 07 ] Available from: https://doi.org/10.1016/j.ygyno.2022.10.022
Artigo de periodico
MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma (2022)
Kang, Eun-Young; Millstein, Joshua; Popovic, Gordana; Meagher, Nicola S.; Bolithon, Adelyn; Talhouk, Aline; Chiu, Derek S.; Anglesio, Michael S.; Leung, Betty; Tang, Katrina; Lambie, Neil; Pavanello, Marina; Ramus, Susan J.; Köbel, Martin; Reis, Francisco José Candido dos
Source: Virchows Archiv. Unidade: FMRP
Subjects: BIOMARCADORES, PROLIFERAÇÃO CELULAR, NEOPLASIAS OVARIANAS, RNA MENSAGEIRO, TAXA DE SOBREVIVÊNCIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
KANG, Eun-Young et al. MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma. Virchows Archiv, v. 480, n. 4, p. 855-871, 2022Tradução . . Disponível em: https://doi.org/10.1007/s00428-021-03232-0. Acesso em: 07 nov. 2024.
APA
Kang, E. -Y., Millstein, J., Popovic, G., Meagher, N. S., Bolithon, A., Talhouk, A., et al. (2022). MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma. Virchows Archiv, 480( 4), 855-871. doi:10.1007/s00428-021-03232-0
NLM
Kang E-Y, Millstein J, Popovic G, Meagher NS, Bolithon A, Talhouk A, Chiu DS, Anglesio MS, Leung B, Tang K, Lambie N, Pavanello M, Ramus SJ, Köbel M, Reis FJC dos. MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma [Internet]. Virchows Archiv. 2022 ; 480( 4): 855-871.[citado 2024 nov. 07 ] Available from: https://doi.org/10.1007/s00428-021-03232-0
Vancouver
Kang E-Y, Millstein J, Popovic G, Meagher NS, Bolithon A, Talhouk A, Chiu DS, Anglesio MS, Leung B, Tang K, Lambie N, Pavanello M, Ramus SJ, Köbel M, Reis FJC dos. MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma [Internet]. Virchows Archiv. 2022 ; 480( 4): 855-871.[citado 2024 nov. 07 ] Available from: https://doi.org/10.1007/s00428-021-03232-0

Digital Library of Intellectual Production of Universidade de São Paulo 2012 - 2024